hATTR-PN Treatment
Jan 05, 2024
Wainua – The Only Approved Medicine for hATTR-PN Treatment
Ionis Pharmaceuticals and AstraZeneca concluded the year 2023 on a positive note as they received the eagerly awaited approval from the FDA for their transthyretin amyloidosis (ATTR) medication, Wainua. In particular, the agency approved the use of the ligand-conjugated antisense oligonucleotide (LICA) medication f...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
